Evidence map›Paper›PMID 42230504›Full record

ArticleBulletin of experimental biology and medicine2026

Circulating DNA-Markers of High Risk for Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease.

A A Ponomaryova, V V Boyarko, L Wang, Z Huang, A A Korobeynikova, P A Gervas, D V Kapitanova, E B Bukreeva, O V Pancova, A A Zarubin and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

A A PonomaryovaCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia. anastasia-ponomaryova@rambler.ru.
V V BoyarkoSiberian State Medical University, Ministry of Health of the Russian Federation, Tomsk, Russia.
L WangInstitute of Advanced Materials, Nanjing University of Posts and Telecommunications, Nanjing, China.
Z HuangInstitute of Advanced Materials, Nanjing University of Posts and Telecommunications, Nanjing, China.
A A KorobeynikovaCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.
P A GervasCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.
D V KapitanovaSiberian State Medical University, Ministry of Health of the Russian Federation, Tomsk, Russia.
E B BukreevaSiberian State Medical University, Ministry of Health of the Russian Federation, Tomsk, Russia.
O V PancovaCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.
A A ZarubinTomsk National Research Medical Center, Research Institute of Medical Genetics, Russian Academy of Sciences, Tomsk, Russia.
V M PerelmuterCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.
N V CherdyntsevaCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.
E V DenisovCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 26 patients with chronic obstructive pulmonary disease (COPD), validation of the marker genes RARB, ZNF260, and DCDC1 was carried out using liquid biopsy technology. Hypermethylation of RARB, ZNF260, and DCDC1 genes in extracellular DNA of the blood plasma was revealed. Post-therapeutic monitoring showed that hypermethylation of the RARB and/or ZNF260 genes was associated with the development of lung cancer in 23% of cases. These findings show the potential of analyzing the epigenetic markers for assessing the risk of lung cancer development in COPD patients.

Indexed as

Biomarkers, TumorCell-Free Nucleic AcidsLung NeoplasmsPulmonary Disease, Chronic ObstructiveAgedDNA MethylationEpigenesis, GeneticFemaleHumansLiquid BiopsyMaleMiddle AgedBiomarkers, TumorCell-Free Nucleic Acidschronic obstructive pulmonary diseaseDNA methylationliquid biopsyprecancerous lesions of the bronchial epithelium

Identifiers

PMID42230504

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.